Sonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates
Sonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates
Sonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates; Both Novel Bifunctional And Monofunctional Fusion Proteins Exhibit Wild-Type Binding To The IL-18 Receptor, Coupled With Undetectable Binding To The Inhibitory IL-18 Binding Protein
Sonnet BioTherapeutics宣佈獲得覆蓋兩種新型免疫治療藥物候選體中變異IL-18的美國專利; 這兩種新型雙重和單一功能融合蛋白均展示出與IL-18受體的野生結合，同時與IL-18抑制結合蛋白的結合無法檢測。
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)
新型雙功能（SON-1411）和單功能（SON-1400）融合蛋白均表現出與IL-18受體（IL-18Rc）的野生結合，同時與IL-18抑制結合蛋白（IL-18BP）的結合不可檢測
IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet's FHAB platform which Sonnet believes could present an important oncology possibility
IL-18在癌症免疫腫瘤學中具有重要意義，並與Sonnet的FHAb平台上的IL-12組合，Sonnet認爲這可能提供重要的腫瘤學可能性
The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic biologics target to IL-18 generating multiple novel cancer drugs
FHAb平台的鎖定和裝載靈活性提供了雙功能載荷能力，可添加另一個協同生物製品靶向IL-18，生成多種新型癌症藥物
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,134,635 entitled "Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same," covering two of its novel drug candidates, SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB), each containing a modified version of recombinant human interleukin-18 (IL-18BPR = Binding Protein Resistant). The patent carries a term effective until June 2044.
新澤西州普林斯頓，2024年11月06日（環球新聞社）- Sonnet BioTherapeutics控股公司（NASDAQ:SONN）（"公司"或"Sonnet"），一家專注於開發靶向免疫療法藥物的臨床階段公司，今天宣佈美國專利局（USPTO）已頒發美國專利號12,134,635，題爲"白細胞介素18（IL-18）變體及包含其的融合蛋白"，覆蓋了其兩種新型藥物候選體SON-1411（IL-18BPR-FHAb-IL12）和SON-1400（IL-18BPR-FHAB），每種藥物均含有重組人白細胞介素18的修飾版本（IL-18BPR =抗結合蛋白）。該專利有效期至2044年6月。
